Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

licencing

- PMLiVE

COVID-19 vaccine protection wanes over time, backing up the need for boosters

While both Pfizer/BioNTech and AstraZeneca’s vaccines offer good protection, a new UK study shows the protection reduces over time and the UK's booster campaign is likely to begin in September

- PMLiVE

Price hike for Pfizer/BioNTech COVID-19 vaccine as UK orders boosters for 2022

The UK will pay £22 a shot, up from £18 previously, as confirmation of the UK's COVID-19 booster campaign for this winter is awaited, while the EU and the US...

- PMLiVE

Valneva’s COVID-19 vaccine to be tested in older people

The trial for VLA2001 will involve people over the age of 56 in New Zealand and aims to generate additional safety and immunogenicity data in older people

- PMLiVE

South Korean company SK bioscience moves into phase 3 trials for its COVID-19 vaccine

Part of the Wave 2 vaccine programme, GBP510 will bolster South Korea’s domestic supply if successful

- PMLiVE

FDA requests further safety trials for AZ, FibroGen’s roxadustat

The response follows concerns over serious thrombotic events and seizures

- PMLiVE

AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria

Real-world data shows similar safety profile for Vaxzevria and mRNA-based jabs

- PMLiVE

AZ raises full-year guidance after completing Alexion acquisition in Q2

Total revenue was up by 31% to $8.2bn and also increased by 24% to $15.2bn for the half year

- PMLiVE

AZ’s PNH therapy Ultomiris wins EU backing to expand use for children

The positive recommendation is based on interim results from a phase 3 trial

- PMLiVE

One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants

New real-world data from Canada shows vaccine efficacy was lower against milder symptomatic disease with one dose

- PMLiVE

AZ licenses pneumonia mAb to Aridis Pharmaceuticals for $11m upfront

The candidate – suvratoxumab – is ready for phase 3 clinical evaluation for the prevention of pneumonia

- PMLiVE

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life...

Avalere Health

- PMLiVE

FDA advisory committee votes against approval of AZ, FibroGen’s roxadustat

Briefing documents published earlier this week raised questions over the safety profile of roxadustat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links